282 related articles for article (PubMed ID: 29681166)
1. Direct-Acting Antivirals to Prevent Vertical Transmission of Viral Hepatitis C: When Is the Optimal Time to Treat?
Cervino L; Hynicka LM
Ann Pharmacother; 2018 Nov; 52(11):1152-1157. PubMed ID: 29681166
[TBL] [Abstract][Full Text] [Related]
2. The Drug-Drug Interaction Potential of Antiviral Agents for the Treatment of Chronic Hepatitis C Infection.
Garrison KL; German P; Mogalian E; Mathias A
Drug Metab Dispos; 2018 Aug; 46(8):1212-1225. PubMed ID: 29695614
[TBL] [Abstract][Full Text] [Related]
3. The pharmacological interactions between direct-acting antivirals for the treatment of chronic hepatitis c and psychotropic drugs.
Roncero C; Villegas JL; Martínez-Rebollar M; Buti M
Expert Rev Clin Pharmacol; 2018 Oct; 11(10):999-1030. PubMed ID: 30199279
[TBL] [Abstract][Full Text] [Related]
4. Treatment of hepatitis C: Results in real life.
Hézode C
Liver Int; 2018 Feb; 38 Suppl 1():21-27. PubMed ID: 29427481
[TBL] [Abstract][Full Text] [Related]
5. New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir.
McConachie SM; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2016; 9(2):287-302. PubMed ID: 26651915
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients.
Taneja S; Duseja A; De A; Kumar V; Ramachandran R; Sharma A; Dhiman RK; Gupta KL; Chawla Y
Nephrology (Carlton); 2018 Sep; 23(9):876-882. PubMed ID: 28703905
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Advances in HCV Genotype 1 Infection: Insights from the Society of Infectious Diseases Pharmacists.
Deming P; Martin MT; Chan J; Dilworth TJ; El-Lababidi R; Love BL; Mohammad RA; Nguyen A; Spooner LM; Wortman SB
Pharmacotherapy; 2016 Feb; 36(2):203-17. PubMed ID: 26846728
[TBL] [Abstract][Full Text] [Related]
9. High rates of hepatitis C virus (HCV) cure using direct-acting antivirals in HIV/HCV-coinfected patients: a real-world perspective.
Hawkins C; Grant J; Ammerman LR; Palella F; Mclaughlin M; Green R; Mcgregor D; Stosor V
J Antimicrob Chemother; 2016 Sep; 71(9):2642-5. PubMed ID: 27330060
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C Virus Resistance Testing in Genotype 1: The Changing Role in Clinical Utility.
Molino S; Martin MT
Ann Pharmacother; 2017 Sep; 51(9):811-816. PubMed ID: 28480743
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
12. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
[TBL] [Abstract][Full Text] [Related]
13. New and Emerging Evidence on the Use of Second-Generation Direct Acting Antivirals for the Treatment of Hepatitis C Virus in Renal Impairment.
Sorbera MA; Friedman ML; Cope R
J Pharm Pract; 2017 Jun; 30(3):359-365. PubMed ID: 26902648
[TBL] [Abstract][Full Text] [Related]
14. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease.
Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T
Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484
[TBL] [Abstract][Full Text] [Related]
15. Unexpected Response Profiles Seen in Hepatitis C Virus-Infected Patients Treated with Sofosbuvir Plus Ribavirin: Five Case Reports.
Saleem K; Wahid B; Ali A; Rafique S; Naz Z; Usman S; Idrees M
Viral Immunol; 2018; 31(6):480-483. PubMed ID: 29694794
[TBL] [Abstract][Full Text] [Related]
16. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
[TBL] [Abstract][Full Text] [Related]
17. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
[TBL] [Abstract][Full Text] [Related]
18. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection.
Toussaint-Miller KA; Andres J
Ann Pharmacother; 2015 Sep; 49(9):1015-30. PubMed ID: 26139639
[TBL] [Abstract][Full Text] [Related]
19. Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis.
Hsu PY; Wei YJ; Lee JJ; Niu SW; Huang JC; Hsu CT; Jang TY; Yeh ML; Huang CI; Liang PC; Lin YH; Hsieh MY; Hsieh MH; Chen SC; Dai CY; Lin ZY; Chen SC; Huang JF; Chang JM; Hwang SJ; Chuang WL; Huang CF; Chiu YW; Yu ML
Clin Mol Hepatol; 2021 Jan; 27(1):186-196. PubMed ID: 33317251
[TBL] [Abstract][Full Text] [Related]
20. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
